DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $26.8 million in its fourth quarter.
The Durham, North Carolina-based company said it had a loss of 13 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share.
The drugmaker posted revenue of $131.5 million in the period.
For the year, the company reported that its loss narrowed to $88.9 million, or 43 cents per share. Revenue was reported as $450.7 million.
BioCryst expects full-year revenue in the range of $560 million to $575 million.
BioCryst shares have climbed 22% since the beginning of the year. The stock has increased 58% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.